14-day Premium Trial Subscription Try For FreeTry Free
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.

FAQ

What is the symbol for Rain Therapeutics Inc. Stock and on which exchange is it traded?
The symbol for Rain Therapeutics Inc. is RAIN and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Rain Therapeutics Inc. Stock?
Rain Therapeutics Inc. holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

How to buy Rain Therapeutics Inc. Stock?
Rain Therapeutics Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Rain Therapeutics Inc. Stock.

What's the current price of Rain Therapeutics Inc. Stock?
As of the end of day on the Apr 24, 2024, the price of an Rain Therapeutics Inc. (RAIN) share was $1.21.

What is the 52-week high and low for Rain Therapeutics Inc. Stock?
The 52-week high for Rain Therapeutics Inc. Stock is $10.50 and the 52-week low is $0.82.

What is the market capitalization of Rain Therapeutics Inc. Stock?
As of the Apr 24, 2024, the market capitalization of Rain Therapeutics Inc. is 44.015M.

When is the next earnings date for Rain Therapeutics Inc.?
The upcoming earnings date for Rain Therapeutics Inc. is May 09, 2024.
Click to get the best stock tips daily for free!

About Rain Therapeutics Inc.

Rain Therapeutics. Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinica... RAIN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT